4:35 PM
 | 
Jan 04, 2013
 |  BC Extra  |  Clinical News

TheraVida's Tolenix meets in Phase II for OAB

TheraVida Inc. (Mountain View, Calif.) said twice-daily Tolenix met the co-primary endpoints of reducing urination frequency and the number of incontinence episodes per day vs. placebo in a Phase II trial...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >